<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD04480000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P08709</UniProt_ID>
  <Seq_Length>466</Seq_Length>
  <Molecule_Weight>51594</Molecule_Weight>
  <KEGG_ID>hsa:2155</KEGG_ID>
  <Orthology_ID>K01320</Orthology_ID>
  <Function_Summary>Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium.</Function_Summary>
  <Catalytic_Mechanism>Selective cleavage of Arg-|-Ile bond in factor X to form factor Xa.</Catalytic_Mechanism>
  <Pfam_ID>PF00008:EGF@@PF00594:Gla@@PF00089:Trypsin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>3</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Serum prothrombin conversion accelerator</Alias>
      <Alias>Proconvertin</Alias>
      <Alias>SPCA</Alias>
      <Alias>Factor VII light chain</Alias>
      <Alias>Factor VII heavy chain</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with calcium ions (Ca2+).</Detail>
      <Keyword>Calcium ion binding</Keyword>
      <Ontology_ID>GO:0005509</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a glycoprotein, a protein that contains covalently bound glycose (monosaccharide) residues. These also include proteoglycans.</Detail>
      <Keyword>Glycoprotein binding</Keyword>
      <Ontology_ID>GO:0001948</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type endopeptidase activity</Keyword>
      <Ontology_ID>GO:0004252</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type peptidase activity</Keyword>
      <Ontology_ID>GO:0008236</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.</Detail>
      <Keyword>Peptidase activity</Keyword>
      <Ontology_ID>GO:0008233</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>73</Position>
      <Original>Leu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>254</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>325</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>64</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>326</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>171</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>302</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>295</Position>
      <Original>Val</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>402</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>88</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>364</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>157</Position>
      <Original>Gly</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>413</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>363</Position>
      <Original>Pro</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>388</Position>
      <Original>Phe</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>82</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>403</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>304</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>354</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>350</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>298</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>425</Position>
      <Original>Gly</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>157</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>408</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>314</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>401</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>323</Position>
      <Original>Leu</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>337</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>251</Position>
      <Original>Ala</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>238</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>79</Position>
      <Original>Glu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>307</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>216</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>154</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>177</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>419</Position>
      <Original>Thr</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>302</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>195</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>251</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>370</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>88</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>363</Position>
      <Original>Pro</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>186</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>194</Position>
      <Original>Pro</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>345</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>125</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>139</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>254</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>391</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>250</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>82</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>364</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>241</Position>
      <Original>Thr</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>358</Position>
      <Original>Met</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>197</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>367</Position>
      <Original>Thr</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>414</Position>
      <Original>Gly</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>304</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>160</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>181</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>398</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>301</Position>
      <Original>His</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>277</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>445</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>389</Position>
      <Original>Cys</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>344</Position>
      <Original>Trp</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>375</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>240</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>121</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>139</Position>
      <Original>Arg</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>272</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>151</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>435</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>198</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>13</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>387</Position>
      <Original>Met</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>422</Position>
      <Original>Val</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>343</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>312</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>352</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>404</Position>
      <Original>Ser</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>391</Position>
      <Original>Gly</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>387</Position>
      <Original>Met</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>358</Position>
      <Original>Met</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>264</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>156</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>85</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>429</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>341</Position>
      <Original>Val</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>266</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>183</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>402</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>189</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>307</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>117</Position>
      <Original>Asn</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>432</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>139</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>321</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>283</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>413</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>332</Position>
      <Original>Thr</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>384</Position>
      <Original>Thr</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>212</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>194</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>138</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>128</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>437</Position>
      <Original>Tyr</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>408</Position>
      <Original>His</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>360</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>157</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>425</Position>
      <Original>Gly</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>120</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The covalent alteration of one or more amino acids occurring in a protein after the protein has been completely translated and released from the ribosome.</Detail>
      <Keyword>Post-translational protein modification</Keyword>
      <Ontology_ID>GO:0043687</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the frequency, rate or extent of the platelet-derived growth factor receptor signaling pathway.</Detail>
      <Keyword>Positive regulation of platelet-derived growth factor receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0010641</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process which directly inhibits any of the steps required for cell death by apoptosis.</Detail>
      <Keyword>Anti-apoptosis</Keyword>
      <Ontology_ID>GO:0006916</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the protein kinase B signaling cascade, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.</Detail>
      <Keyword>Positive regulation of protein kinase B signaling cascade</Keyword>
      <Ontology_ID>GO:0051897</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate, or extent of leukocyte chemotaxis.</Detail>
      <Keyword>Positive regulation of leukocyte chemotaxis</Keyword>
      <Ontology_ID>GO:0002690</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.</Detail>
      <Keyword>Proteolysis</Keyword>
      <Ontology_ID>GO:0006508</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The gamma-carboxylation of peptidyl-glutamic acid; catalyzed by the vitamin K dependent gamma-glutamyl carboxylase.</Detail>
      <Keyword>Peptidyl-glutamic acid carboxylation</Keyword>
      <Ontology_ID>GO:0017187</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the directed movement of a motile cell or organism towards a higher concentration in a concentration gradient of a specific chemical.</Detail>
      <Keyword>Positive regulation of positive chemotaxis</Keyword>
      <Ontology_ID>GO:0050927</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.</Detail>
      <Keyword>Hemostasis</Keyword>
      <Ontology_ID>GO:0007599</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A protein activation cascade that contributes to blood coagulation and consists of the self-limited process linking exposure and activation of tissue factor to the activation of clotting factor X.</Detail>
      <Keyword>Blood coagulation, extrinsic pathway</Keyword>
      <Ontology_ID>GO:0007598</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>95</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>86</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>67</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>85</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>66</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>80</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>89</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>76</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>74</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
    <PTM>
      <Position>123</Position>
      <PTM_Type>(3R)-3-hydroxyaspartate</PTM_Type>
    </PTM>
    <PTM>
      <Position>79</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MVSQALRLLCLLLGLQGCLAAGGVAKASGGETRDMPWKPGPHRVFVTQEEAHGVLHRRRRANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP</Protein_Seq>
    <DNA_Seq>GTCAGTCCCATGGGGAATGTCAACAGGCAGGGGCAGCACTGCAGAGATTTCATCATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGGCCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGCGCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAGCAGTGCTCCTTCGAGGAGGCCCGGGAGATCTTCAAGGACGCGGAGAGGACGAAGCTGTTCTGGATTTCTTACAGTGATGGGGACCAGTGTGCCTCAAGTCCATGCCAGAATGGGGGCTCCTGCAAGGACCAGCTCCAGTCCTATATCTGCTTCTGCCTCCCTGCCTTCGAGGGCCGGAACTGTGAGACGCACAAGGATGACCAGCTGATCTGTGTGAACGAGAACGGCGGCTGTGAGCAGTACTGCAGTGACCACACGGGCACCAAGCGCTCCTGTCGGTGCCACGAGGGGTACTCTCTGCTGGCAGACGGGGTGTCCTGCACACCCACAGTTGAATATCCATGTGGAAAAATACCTATTCTAGAAAAAAGAAATGCCAGCAAACCCCAAGGCCGAATTGTGGGGGGCAAGGTGTGCCCCAAAGGGGAGTGTCCATGGCAGGTCCTGTTGTTGGTGAATGGAGCTCAGTTGTGTGGGGGGACCCTGATCAACACCATCTGGGTGGTCTCCGCGGCCCACTGTTTCGACAAAATCAAGAACTGGAGGAACCTGATCGCGGTGCTGGGCGAGCACGACCTCAGCGAGCACGACGGGGATGAGCAGAGCCGGCGGGTGGCGCAGGTCATCATCCCCAGCACGTACGTCCCGGGCACCACCAACCACGACATCGCGCTGCTCCGCCTGCACCAGCCCGTGGTCCTCACTGACCATGTGGTGCCCCTCTGCCTGCCCGAACGGACGTTCTCTGAGAGGACGCTGGCCTTCGTGCGCTTCTCATTGGTCAGCGGCTGGGGCCAGCTGCTGGACCGTGGCGCCACGGCCCTGGAGCTCATGGTCCTCAACGTGCCCCGGCTGATGACCCAGGACTGCCTGCAGCAGTCACGGAAGGTGGGAGACTCCCCAAATATCACGGAGTACATGTTCTGTGCCGGCTACTCGGATGGCAGCAAGGACTCCTGCAAGGGGGACAGTGGAGGCCCACATGCCACCCACTACCGGGGCACGTGGTACCTGACGGGCATCGTCAGCTGGGGCCAGGGCTGCGCAACCGTGGGCCACTTTGGGGTGTACACCAGGGTCTCCCAGTACATCGAGTGGCTGCAAAAGCTCATGCGCTCAGAGCCACGCCCAGGAGTCCTCCTGCGAGCCCCATTTCCCTAGCCCAGCAGCCCTGGCCTGTGGAGAGAAAGCCAAGGCTGCGTCGAACTGTCCTGGCACCAAATCCCATATATTCTTCTGCAGTTAATGGGGTAGAGGAGGGCATGGGAGGGAGGGAGAGGTGGGGAGGGAGACAGAGACAGAAACAGAGAGAGACAGAGACAGAGAGAGACTGAGGGAGAGACTCTGAGGACATGGAGAGAGACTCAAAGAGACTCCAAGATTCAAAGAGACTAATAGAGACACAGAGATGGAATAGAAAAGATGAGAGGCAGAGGCAGACAGGCGCTGGACAGAGGGGCAGGGGAGTGCCAAGGTTGTCCTGGAGGCAGACAGCCCAGCTGAGCCTCCTTACCTCCCTTCAGCCAAGCCCACCTGCACGTGATCTGCTGGCCTCAGGCTGCTGCTCTGCCTTCATTGCTGGAGACAGTAGAGGCATGAACACACATGGATGCACACACACACACGCCAATGCACACACACAGAGATATGCACACACACGGATGCACACACAGATGGTCACACAGAGATACGCAAACACACCGATGCACACGCACATAGAGATATGCACACACAGATGCACACACAGATATACACATGGATGCACGCACATGCCAATGCACGCACACATCAGTGCACACGGATGCACAGAGATATGCACACACCGATGTGCGCACACACAGATATGCACACACATGGATGAGCACACACACACCAATGCGCACACACACCGATGTACACACACAGATGCACACACAGATGCACACACACCGATGCTGACTCCATGTGTGCTGTCCTCTGAAGGCGGTTGTTTAGCTCTCACTTTTCTGGTTCTTATCCATTATCATCTTCACTTCAGACAATTCAGAAGCATCACCATGCATGGTGGCGAATGCCCCCAAACTCTCCCCCAAATGTATTTCTCCCTTCGCTGGGTGCCGGGCTGCACAGACTATTCCCCACCTGCTTCCCAGCTTCACAATAAACGGCTGCGTCTCCTCCGCACACCTGTGGTGCCTGCCACCCACTGGGTTGCCCATGATTCATTTTTGGAGCCCCCGGTGCTCATCCTCTGAGATGCTCTTTTCTTTCACAATTTTCAACATCACTGAAATGAACCCTCACATGGAAGCTATTTTTTAAAAACAAAAGCTGTTTGATAGATGTTTGAGGCTGTAGCTCCCAGGATCCTGTGGAATTGGATGTTCTCTCCCTGCCACAGCCCTTGTCAATGATATTTCACAGAGACCCTGGGAGCACCTGCTCAAGAGTCAGGGACACACGCATCACTAAATGCAAGTTCCCAGGCCCTGGCTGCAGTGGGAGGACCTGGCAAGCTGCACTCTTGCTGAGTCCCCAGGGTGGTGGAAGAAGAATGAGAAACACATGAACAGAGAAATGGGGAGGTGACAAACAGTGCCCCCACTCAGACTCCGGCAAGCACGGCTCAGAGAGTGGACTCGATGCCATCCCTGCAGGGCCGTCCTGGGCACCACTGGCACTCACAGCAGCAAGGTGGGCACCATTGGCACTCACAGCAGCAAGGCAGGCACCAGCAACCCACCTCGGGGGCACTCAGGCATCATCTACTTCAGAGCAGACAGGGTCTATGAACTACAGCCGTGGGCTGCTTCCAAGGCACCCTGCTCTTGTAAATAAAGTTTTATGGGAACACAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Plasma</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endoplasmic reticulum lumen</CellLocal>
      <Ontology_ID>GO:0005788</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Golgi lumen</CellLocal>
      <Ontology_ID>GO:0005796</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>F7</Gene_Name>
    <Gene_ID>2155</Gene_ID>
    <Genbank_ACCN>NM_000131</Genbank_ACCN>
    <Protein_ACCN>NP_000122</Protein_ACCN>
    <HGNC_ID>3544</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2155</Gene_URL>
    <UCSC_ID>uc001vsw.3</UCSC_ID>
    <EMBL_ID>ENSG00000057593</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Hypercholesterolemia</Disease_Name>
      <Disease_Detail>Hypercholesterolemia</Disease_Detail>
      <Disease_DB>HYP095</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypercholesterolemia?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor V Deficiency</Disease_Name>
      <Disease_Detail>Factor V Deficiency</Disease_Detail>
      <Disease_DB>FCT006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_v_deficiency?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vitamin K Deficiency Hemorrhagic Disease</Disease_Name>
      <Disease_Detail>Vitamin K Deficiency Hemorrhagic Disease</Disease_Detail>
      <Disease_DB>VTM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vitamin_k_deficiency_hemorrhagic_disease?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Xi Deficiency</Disease_Name>
      <Disease_Detail>Factor Xi Deficiency</Disease_Detail>
      <Disease_DB>FCT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_xi_deficiency?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ischemic Heart Disease</Disease_Name>
      <Disease_Detail>Ischemic Heart Disease</Disease_Detail>
      <Disease_DB>ISC006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ischemic_heart_disease?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Vii Deficiency</Disease_Name>
      <Disease_Detail>Factor Vii Deficiency</Disease_Detail>
      <Disease_DB>FCT007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_vii_deficiency?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carotid Intimal Medial Thickness</Disease_Name>
      <Disease_Detail>Carotid Intimal Medial Thickness</Disease_Detail>
      <Disease_DB>CRT018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carotid_intimal_medial_thickness?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myocardial Infarction, Decreased</Disease_Name>
      <Disease_Detail>Myocardial Infarction</Disease_Detail>
      <Disease_DB>MYC065</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myocardial_infarction_decreased?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myocardial Infarction</Disease_Name>
      <Disease_Detail>Myocardial Infarction</Disease_Detail>
      <Disease_DB>MYC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myocardial_infarction?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor X Deficiency</Disease_Name>
      <Disease_Detail>Factor X Deficiency</Disease_Detail>
      <Disease_DB>FCT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_x_deficiency?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dubin-Johnson Syndrome</Disease_Name>
      <Disease_Detail>Dubin-Johnson Syndrome</Disease_Detail>
      <Disease_DB>DBN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dubin_johnson_syndrome?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemorrhagic Disease</Disease_Name>
      <Disease_Detail>Hemorrhagic Disease</Disease_Detail>
      <Disease_DB>HMR003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemorrhagic_disease?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Viii Deficiency</Disease_Name>
      <Disease_Detail>Factor Viii Deficiency</Disease_Detail>
      <Disease_DB>FCT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_viii_deficiency?search=F7#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemophilia B</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>HMP004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemophilia_b?search=F7#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of active site inhibited coagulation factor VIIA in complex with soluble tissue factor</PDB_Title>
      <PDB_ID>2PUQ</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PUQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa</PubMed_Title>
      <Author>Larsen, K.S., et al.</Author>
      <Journal>Biochem.J.(2007)405:429-438</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17456045?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Discovery of Novel Heterocyclic Factor VIIa Inhibitors</PDB_Title>
      <PDB_ID>2F9B</PDB_ID>
      <Resolution>2.54</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F9B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of novel heterocyclic factor VIIa inhibitors.</PubMed_Title>
      <Author>Rai, R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:2270-2273</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16460932?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Glu-Gly-Arg-Chloromethyl Ketone-Factor VIIa/Soluble Tissue Factor Complex</PDB_Title>
      <PDB_ID>2B8O</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2B8O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of Factor VIIa/soluble Tissue Factor complexed with Glu-Gly-Arg-Chloromethyl ketone</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Benzamidine-Factor VIIa/Soluble Tissue Factor complex.</PDB_Title>
      <PDB_ID>2AER</PDB_ID>
      <Resolution>1.87</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AER</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>High Resolution Structures of p-Aminobenzamidine- and Benzamidine-VIIa/Soluble Tissue Factor: Unpredicted conformation of the 192-193 peptide bond and mapping of Ca2+, Mg2+, Na+ and Zn2+ sites in factor VIIa</PubMed_Title>
      <Author>Bajaj, S.P., et al.</Author>
      <Journal>J.Biol.Chem.(2006)281:24873-24888</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16757484?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Factor VIIA-Tissue Factor Complexed with ethylsulfonamide-D-5-(3-carboxybenzyloxy)-Trp-Gln-p-aminobenzamidine</PDB_Title>
      <PDB_ID>2ZZU</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZZU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of peptidomimetic factor VIIa inhibitors</PubMed_Title>
      <Author>Shiraishi, T., et al.</Author>
      <Journal>Chem.Pharm.Bull.(2010)58:38-44</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20045964?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Novel 5-Azaindole Factor VIIa Inhibitors</PDB_Title>
      <PDB_ID>2FLR</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FLR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel 5-azaindole factor VIIa inhibitors.</PubMed_Title>
      <Author>Riggs, J.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:3197-3200</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16621549?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of DFPR-VIIa/sTF</PDB_Title>
      <PDB_ID>2FIR</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FIR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>High Resolution Structures of p-Aminobenzamidine- and Benzamidine-VIIa/Soluble Tissue Factor: Unpredicted conformation of the 192-193 peptide bond and mapping of Ca2+, Mg2+, Na+ and Zn2+ sites in factor VIIa</PubMed_Title>
      <Author>Bajaj, S.P., et al.</Author>
      <Journal>J.Biol.Chem.(2006)281:24873-24888</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16757484?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure analysis of human Factor VIIa , Souluble tissue factor complexed with BCX-3607</PDB_Title>
      <PDB_ID>2EC9</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2EC9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure analysis of human Factor VIIa , Souluble tissue factor complexed with BCX-3607</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of active site inhibited coagulation factor VIIA mutant in complex with soluble tissue factor</PDB_Title>
      <PDB_ID>3ELA</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ELA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mechanism of the Ca2+-induced enhancement of the intrinsic factor VIIa activity</PubMed_Title>
      <Author>Bjelke, J.R., et al.</Author>
      <Journal>J.Biol.Chem.(2008)283:25863-25870</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18640965?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Complex of Active-site Inhibited Human Coagulation Factor VIIa with Human Soluble Tissue Factor in the Presence of Ca2+, Mg2+, Na+, and Zn2+</PDB_Title>
      <PDB_ID>2A2Q</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2A2Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>High resolution structures of p-aminobenzamidine- and benzamidine-VIIa/soluble tissue factor: unpredicted conformation of the 192-193 peptide bond and mapping of Ca2+, Mg2+, Na+, and Zn2+ sites in factor VIIa.</PubMed_Title>
      <Author>Bajaj, S.P., et al.</Author>
      <Journal>J.Biol.Chem.(2006)281:24873-24888</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16757484?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor VIIa Inhibitors: Chemical Optimization, Preclinical Pharmacokinetics, Pharmacodynamics, and Efficacy in a Baboon Thrombosis Model</PDB_Title>
      <PDB_ID>2B7D</PDB_ID>
      <Resolution>2.24</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2B7D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.</PubMed_Title>
      <Author>Young, W.B., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:2037-2041</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16412633?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Discovery of a Novel Hydroxy Pyrazole Based Factor IXa Inhibitor</PDB_Title>
      <PDB_ID>2FLB</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FLB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of novel hydroxy pyrazole based factor IXa inhibitor.</PubMed_Title>
      <Author>Vijaykumar, D., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:2796-2799</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16487703?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human factor viia-tissue factor complexed with benzylsulfonamide-D-ile-gln-P-aminobenzamidine</PDB_Title>
      <PDB_ID>2ZP0</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZP0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Peptide Mimetic Factor VIIa Inhibitor: Importance of Hydrophilic Pocket in S2 Site to Improve Selectivity aganist Thrombin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Complex Between the Peptide Exosite Inhibitor E-76 and Coagulation Factor VIIA</PDB_Title>
      <PDB_ID>1DVA</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DVA</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04480002</ASD_Ligand>
      <PubMed_Title>Peptide exosite inhibitors of factor VIIa as anticoagulants.</PubMed_Title>
      <Author>Dennis, M.S., et al.</Author>
      <Journal>Nature(2000)404:465-470</Journal>
      <PubMed_ID>10761907</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF FACTOR VII.STF COMPLEXED WITH PD0297121</PDB_Title>
      <PDB_ID>2C4F</PDB_ID>
      <Resolution>1.72</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2C4F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Discovery of Fluoropyridine-Based Inhibitors of the Factor Viia/Tf Complex--Part 2</PubMed_Title>
      <Author>Kohrt, J.T., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:1060</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16289811?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>ORALLY AVAILABLE FACTOR7A INHIBITOR</PDB_Title>
      <PDB_ID>2BZ6</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2BZ6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Dose-Dependant Antithrombotic Activity of an Orally Active Tissue Factor/Factor Viia Inhibitor without Concomitant Enhancement of Bleeding Propensity.</PubMed_Title>
      <Author>Groebke-Zbinden, K., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2006)14:5357</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16621574?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human factor viia-tissue factor complexed with highly selective peptide inhibitor</PDB_Title>
      <PDB_ID>2ZWL</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZWL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human factor viia-tissue factor complexed with highly selective peptide inhibitor</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of a ternary complex of factor VIIa/tissue factor and 2-[[6-[3-(aminoiminomethyl)phenoxy]-3,5-difluro-4-[(1-methyl-3-phenylpropyl)amino]-2-pyridinyl]oxy]-benzoic acid</PDB_Title>
      <PDB_ID>2AEI</PDB_ID>
      <Resolution>2.52</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AEI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex.</PubMed_Title>
      <Author>Kohrt, J.T., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2005)15:4752-4756</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16125385?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Short Factor VIIa with a small molecule inhibitor</PDB_Title>
      <PDB_ID>1YGC</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YGC</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04480003</ASD_Ligand>
      <PubMed_Title>A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo.</PubMed_Title>
      <Author>Olivero, A.G., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:9160-9169</Journal>
      <PubMed_ID>15632123</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of a ternary complex of Factor VIIa/Tissue Factor/Pyrazinone Inhibitor</PDB_Title>
      <PDB_ID>1Z6J</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Z6J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design and synthesis of pyrazinones containing novel P1 'side pocket' moieties as inhibitors of TF/VIIa.</PubMed_Title>
      <Author>Schweitzer, B.A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2005)15:3006-3011</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15913999?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Complex of active site inhibited human blood coagulation factor VIIA with human recombinant soluble tissue factor</PDB_Title>
      <PDB_ID>1DAN</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DAN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor.</PubMed_Title>
      <Author>Banner, D.W., et al.</Author>
      <Journal>Nature(1996)380:41-46</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8598903?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04610</Pathway_ID>
      <Pathway_Title>Complement and coagulation cascades</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.ia.b.c.cj.html</SCOP_URL>
    <CATH_Class>Class 2: Mainly Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1cvw</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,96,Arg;site,103,Ser;site,124,Gln;site,130,Cys;site,132,Cys;site,137,Glu;site,138,Gly;site,139,Arg;site,145,Lys</Site_Detail>
      <Site_Reference>Banner DW, et al. Nature. 1996,380(6569):41-46.;Zhang E, et al. J Mol Biol. 1999,285(5):2089-2104.</Site_Reference>
      <Site_Type>Protein-induced</Site_Type>
      <PubMed_ID>8598903;9925787</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.4.21.21</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/4/21/21.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD04480001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04480002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04480003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>